Abeona buys Ellodi's EoE drug ABO-801 for $20M in stock and lines up $30M private placement

On November 9, 2026, Abeona Therapeutics announced it acquired APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals. ABO-801 is a once-daily oral fluticasone propionate tablet for eosinophilic esophagitis with FDA Orphan Drug designation. The deal involves no upfront cash, and Abeona also signed a $30 million private placement; it plans to start a new Phase 3 study in Q2 2027, after two earlier Phase 3 studies missed their co-primary symptom endpoint.

09 Nov 2026 · Abeona Therapeutics Inc. ABEO · Company news

Company's press release (SEC filing): Abeona Therapeutics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Abeona buys Ellodi's EoE drug ABO-801 for $20M in stock and lines up $30M private placement

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq